All In Biotech

Drug Trial Radar · NCT01313676

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease

Last checked: Nov 19, 2026Latest source record: Aug 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 16,568 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

16,568

Actual

Start

Jan 25, 2011

Primary completion

Jul 15, 2015

Study completion Jul 15, 2015

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Mar 14, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • fluticasone furoate/vilanterolDrug

    100/25mcg given once daily via novel dry powder inhaler

  • fluticasone furoateDrug

    100mcg given once daily via novel dry powder inhaler

  • vilanterolDrug

    25mcg given once daily via novel dry powder inhaler

  • PlaceboOther

    placebo comparator once daily via novel dry powder inhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End DateTime frame: From the date of randomization until date of death due to any cause (average of 2 study years)

Locations

1,611 sites in 44 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Andalusia, Alabama

  • GSK Investigational Site

    Athens, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Huntsville, Alabama

  • GSK Investigational Site

    Huntsville, Alabama

  • GSK Investigational Site

    Mobile, Alabama

  • GSK Investigational Site

    Mobile, Alabama

  • GSK Investigational Site

    Montgomery, Alabama

  • GSK Investigational Site

    Montgomery, Alabama

  • GSK Investigational Site

    Muscle Shoals, Alabama

  • GSK Investigational Site

    Ozark, Alabama

  • GSK Investigational Site

    Pell City, Alabama

  • GSK Investigational Site

    Tuscumbia, Alabama

  • GSK Investigational Site

    Flagstaff, Arizona

  • GSK Investigational Site

    Glendale, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Scottsdale, Arizona

  • GSK Investigational Site

    Sierra Vista, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Fayetteville, Arkansas

  • GSK Investigational Site

    Jonesboro, Arkansas

  • GSK Investigational Site

    Anaheim, California

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Cerritos, California

  • GSK Investigational Site

    Encinitas, California

  • GSK Investigational Site

    Foothill Ranch, California

  • GSK Investigational Site

    Fountain Valley, California

  • GSK Investigational Site

    Garden Grove, California

  • GSK Investigational Site

    Gold River, California

  • GSK Investigational Site

    Huntington Beach, California

  • GSK Investigational Site

    Huntington Park, California

  • GSK Investigational Site

    Lakewood, California

  • GSK Investigational Site

    Lancaster, California

  • GSK Investigational Site

    Loma Linda, California

  • GSK Investigational Site

    Long Beach, California

Showing 40 of 1,611 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.